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The accompanying article addresses the use of anti
psychotic medication in the Texasprison system and
raises manychallenging and difficult issues worthyof
discussion and further examination. As the associ
ated article and a growing body of literature docu
ment, an increasing number of severely and persis
tentlymentallyillare incarcerated in the nation's jails
and prisons.1-3 A corollary to this assertion is the
growing need for treatmentof these populations of
individuals with psychosis or severe functional im
pairment. I would like to take this opportunity to
elaborate on several issues raised by this thoughtful
article: thediagnoses andtarget symptomatology for
antipsychotic medication, medication selection and
management, and the issues of potential racial and
gender bias in the treatmentof incarcerated patients.
Issues of Diagnosis and Indications for
Use of Antipsychotic Medication
Clearly, antipsychotic medication is indicated in
the treatment of the schizophrenias and schizophre
nia-like disorders, aswell as the psychoses associated
with bipolar disorder, psychotic depression, and
many drug intoxication states.4 There are few, ifany,
concerns about the appropriateness of the medica
tions as a broad class there.5 Of particular relevance
to the incarcerated populationareoff-indication uses
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suchasthe treatmentofsevere impulsivity, impulsive
aggression, or other disturbing behaviors that have
not been responsive to behavioral, psychotherapeu
tic, or other kinds of medication intervention.6,7
Medication Selection and Management
When we look at these issues, it is important to
think about the literature that helps to define the
relative indications of both the typical or the tradi
tional antipsychotic medications, as well as the new
class of atypical antipsychotic medications. These
atypical antipsychotics are arguably more effective
and more specific, both in the treatment and in the
management ofthe diagnosable psychoses,4,5 as well
as the other indications for which these medications
might be used as outlined previously.6,7
I would like to focus on an interesting negative
finding in thearticle: no particular selection bias was
found in the use of atypical versus typical antipsy
chotic medications where there was a history of vio
lent behavior in someone with a psychotic disorder.
Growing literature suggests that serotonin-selective
reuptake inhibitors, anticonvulsants, antipsychotics,
and other potential medicationsare beneficial in the
treatment ofviolent behavior in the context of men
tal illness.8-10 Although the article did not provide
data allowing us to determine whether these other
(nonantipsychotic) classes of medication were being
used in thissubset of violent, psychotic individuals,
nevertheless, there are preliminary data to support
the preferential use of atypical antipsychotics in the
treatment of violence in the context of chronic psy
chosis,11-14 with many methodological caveats
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noted.15 Given the potentially improved rate of ad
herenceto atypicalantipsychotic medication (see the
following discussion), this isa factor worth consider
ingin this population. However, there isa paucity of
dataexamining this issue in the correctional environ
ment.This lackofdata argues for the needto address
explicitly the question of the relative benefit of the
atypical antipsychotics and the treatment of aggres
sion, violence, and, particularlyand commonly, im
pulsive violence, with (or without) associated psy
chosis in the correctional setting.
As is known by clinicians involved in the delivery
of psychiatric services in correctional settings, there
are unique challenges to these environments and the
data derived from community-based service delivery
may not beapplicable. That said, several questions of
clinical relevance readilycome to mind:
1. Are adverse reactions more/less common or dif
ferent in response to antipsychotics by incarcerated
and other clinical samples? To my knowledge, no
data are available at this time on this issue.
2. Do incarcerated persons adhere to antipsy
chotic regimens at a rate differing from community
samples because of perhaps different predictive fac
tors (e.g., psychopathy, comorbid substance abuse
history, fear of lossofalertness, and resultantvulner
ability to victimization)? At least one preliminary
study16 supports improved adherence with atypical
versus typical antipsychotics in a correctional setting
consistent with findings in the community.17
These very limited data would tend to supportatyp
ical use in correctional settings in parallel to their
community use. Further studies in this area are
clearly needed.
3. Does the relative costof atypical antipsychotics
contribute to reduced or differential use in a correc
tional environment? The dynamics of funding and
reimbursement of funding maycome into playhere
as well as in the community. Although the phar-
macoeconomics of atypical antipsychotic use in the
communityare fairly clear, balancing the highercost
of atypical antipsychotics with decreased service uti
lization and improved functioning,20,21 extensions
of these studies into correctional environments
would have to take into account the specific funding
mechanism under which each system operates.
Funding issues include potential for reduced distur
bances in the jail or prison, reduced need for higher
cost infirmary settings, ability of the inmate patient
to function ina general populationsettingwith fewer
custody and mental health needs, and so forth.22
Potential Racial Bias in Diagnosis and
Medication Selection
In thisnation, therearesubstantial data to suggest
that incarcerated individuals are disproportionately
minorities; within that group, a disproportionate
number are African-Americans.23 One of the con
cerns raised in the associated article is that there were
a small number of African-Americans treated with
atypical antipsychotic medication compared with
the moretraditional antipsychotic medications. This
is of real significance for several reasons. The first is
that African-Americans, in particular, are more sus
ceptible to tardivedystonias and dyskinesias asacon
sequence of treatmentwith the typical antipsychotic
medications than arediagnostically similar members
of otherethnic groups.24,25 These dataclearly raise
concerns about the potential for racial bias in the
selection of antipsychotic medication. In the discus
sion section, the authors reasonablyraise the follow
ing question. Given the absence of data to the con
trary, might there have been a disproportionate
number ofAfrican-American individuals in the com
munity admitted to the correctional system on the
typical antipsychotic medications? The apparent ra
cial bias within the correctional system may simply
reflect an ongoing bias that may exist in the commu
nity regarding diagnosis and/or treatment.26-28 The
data are not immediately available to address that
concern. This does raise an issue that our society
needs to confront both in terms ofthe issues ofselec
tion bias, as well as treatment bias in the context of
the overall apparent racial bias that leads toward in
carceration in disproportionate numbers.
It may safely bestated, then, that targeted studies
need to beconducted examining the potential issues
of racial bias andwhat might becontributory factors
oftreatment on the one hand and treatment selection
on the other. Further, data are veryhard to come by
at this stage of the specific diagnoses of individuals
and whether the racial or cultural biases in the diag
nostic preferences in the community26-28 persist
during incarceration. This article serves to put uson
notice that it is incumbent on us as clinical research
ers to address these issues, separate from any of the
criminal justice issues perse.
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Potential Gender Bias in
Medication Selection
Focusing for a moment on gender issues that are
raised, a fascinating finding here has to do with the
increased frequency oftreatment ofwomen withtyp
ical antipsychotics in parallel with and in addition to
the finding of racial bias. What we have learned in
recent years is the critical need to conduct studies of
potential gender-specific responses to treatment.
This clearly applies to specific disorders such as the
schizophrenias, the bipolardisorders, or other disor
ders in which atypical antipsychotic medication may
be used for the treatment of psychotic processes.
Currently, limited data exist on gender differences
in schizophrenia and response to treatment.29-32
Therefore, it is incumbenton us to begin examining
withmuch more targeted care and concern potential
gender biases in diagnosis and subsequent treatment
selection with the need for the research underpin
nings to beable toexamine potential gender selectiv
ity in response to different medications given a spe
cific diagnosis.
Use of Practice Guidelines
One approach that may help us address many of
these concerns is beginning to receive widespread
attention in psychiatric practice: the use of prescrib
ingguidelines. Although several different approaches
exist,33,34 the potential benefit of applying algo
rithm-supported decision making in a correctional
setting is substantial. Algorithmic approaches to sys
tematizing prescribing practices mayhelp to improve
quality of care as it eliminates unwanted or unin
tended biases. The considered approach to decision
making andthescheduled re-evaluation of therapeu
tic benefit and side-effect burden make the applica
tion of practice guidelines ideal in such a regulated
environment as correctional settings. The concomi
tant psychoeducation that is part of some practice
guidelines34 may work further to enhance medica
tion effects. Although applied in limited settings to
date,35 and not yet comprehensively applied to any
correctional setting, the potential benefits of thisap
proach clearly should encourage us to pursue this
opportunity rigorously.
It is the hope of this author that the study pre
sented here will be the harbinger of many similar
studies that will allow us to examine more carefully
the treatment of the mentally ill who are incarcer
ated, how we might optimize the careof those indi
viduals, and howwemay bringstate-of-the-art stan
dards to the careof these populations.
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